- Home
- GAME vs GBIO Comparison
GAME vs GBIO Comparison
Compare GAME & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- GBIO
- Stock Information
- Founded
- GAME 2011
- GBIO 2016
- Country
- GAME United States
- GBIO United States
- Employees
- GAME N/A
- GBIO N/A
- Industry
- GAME
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- GAME
- GBIO Health Care
- Exchange
- GAME Nasdaq
- GBIO Nasdaq
- Market Cap
- GAME 27.2M
- GBIO 29.2M
- IPO Year
- GAME 2009
- GBIO 2020
- Fundamental
- Price
- GAME $1.60
- GBIO $0.41
- Analyst Decision
- GAME Strong Buy
- GBIO Strong Buy
- Analyst Count
- GAME 3
- GBIO 4
- Target Price
- GAME $3.67
- GBIO $7.33
- AVG Volume (30 Days)
- GAME 20.3M
- GBIO 2.0M
- Earning Date
- GAME 08-13-2025
- GBIO 08-06-2025
- Dividend Yield
- GAME N/A
- GBIO N/A
- EPS Growth
- GAME N/A
- GBIO N/A
- EPS
- GAME N/A
- GBIO N/A
- Revenue
- GAME $99,579,536.00
- GBIO $24,556,000.00
- Revenue This Year
- GAME $6.08
- GBIO N/A
- Revenue Next Year
- GAME $21.94
- GBIO N/A
- P/E Ratio
- GAME N/A
- GBIO N/A
- Revenue Growth
- GAME 77.06
- GBIO 146.47
- 52 Week Low
- GAME $0.50
- GBIO $0.30
- 52 Week High
- GAME $2.87
- GBIO $3.65
- Technical
- Relative Strength Index (RSI)
- GAME 57.43
- GBIO 50.87
- Support Level
- GAME $1.47
- GBIO $0.32
- Resistance Level
- GAME $2.82
- GBIO $0.59
- Average True Range (ATR)
- GAME 0.36
- GBIO 0.05
- MACD
- GAME 0.05
- GBIO 0.02
- Stochastic Oscillator
- GAME 41.89
- GBIO 34.16
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.